Literature DB >> 2261822

Weight gain associated with improved glycemic control in population-based sample of subjects with type I diabetes.

R R Wing1, R Klein, S E Moss.   

Abstract

Previous studies have suggested that weight gain is an identifiable risk of efforts to lower blood glucose with intensive insulin therapy in type I (insulin-dependent) diabetic subjects. This study examined this relationship in a population-based sample of type I diabetic subjects participating in the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Four hundred five adults (aged greater than or equal to 21 yr) with type I diabetes, who were diagnosed before age 30 yr, were studied from 1980 to 1982 and in a follow-up examination from 1984 to 1986. Weight gain over the 4-yr interval averaged 1.8 +/- 5.9 kg. Weight gain was significantly associated (r = -0.26, P less than 0.001) with improvements in glycosylated hemoglobin levels; the quartile of subjects with the greatest improvements in glycemic control gained 3.4 kg, whereas the quartile of subjects with the smallest improvements in glycemic control lost 0.6 kg. Weight gain was also correlated with increases in the number of shots of insulin per day and change in the treatment regimen from one type of insulin to a combination of short- and long-acting insulins. These results suggest that weight gain may be an adverse consequence of improved glycemic control. Efforts to better understand the mechanism explaining weight gain and to prevent weight gain are needed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2261822     DOI: 10.2337/diacare.13.11.1106

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  13 in total

1.  Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating β-catenin and CREB activities.

Authors:  Shenghao Liu; Rui Liu; Yu-Ting Chiang; Lifang Song; Xiaoming Li; Tianru Jin; Qinghua Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-07-17       Impact factor: 4.310

Review 2.  Glycemic control and complications of diabetes mellitus.

Authors:  I B Hirsch
Journal:  West J Med       Date:  1995-05

3.  Tissue selectivity of insulin detemir action in vivo.

Authors:  A M Hennige; T Sartorius; O Tschritter; H Preissl; A Fritsche; P Ruth; H-U Häring
Journal:  Diabetologia       Date:  2006-03-29       Impact factor: 10.122

4.  Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial.

Authors: 
Journal:  Diabetes Care       Date:  2001-10       Impact factor: 19.112

5.  Temporal trends in the treatment of pediatric type 1 diabetes and impact on acute outcomes.

Authors:  Britta M Svoren; Lisa K Volkening; Deborah A Butler; Elaine C Moreland; Barbara J Anderson; Lori M B Laffel
Journal:  J Pediatr       Date:  2007-03       Impact factor: 4.406

6.  Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus.

Authors:  N de Fine Olivarius; A H Andreasen; V Siersma; B Richelsen; H Beck-Nielsen
Journal:  Diabetologia       Date:  2006-07-14       Impact factor: 10.122

7.  Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial.

Authors:  Jonathan Q Purnell; Raj K Dev; Michael W Steffes; Patricia A Cleary; Jerry P Palmer; Irl B Hirsch; John E Hokanson; John D Brunzell
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

8.  Weight gain trajectories and obesity rates in intensive and conventional treatments of type 1 diabetes from the DCCT compared with a control population without diabetes.

Authors:  Nichole E Carlson; Ken W Horton; John E Hokanson; Patricia A Cleary; David R Jacobs; John D Brunzell; Jonathan Q Purnell
Journal:  Diabet Med       Date:  2022-01-26       Impact factor: 4.213

9.  Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects.

Authors:  Manfred Hallschmid; Kamila Jauch-Chara; Oliver Korn; Matthias Mölle; Björn Rasch; Jan Born; Bernd Schultes; Werner Kern
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

10.  Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.

Authors:  J Q Purnell; J E Hokanson; S M Marcovina; M W Steffes; P A Cleary; J D Brunzell
Journal:  JAMA       Date:  1998-07-08       Impact factor: 157.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.